Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C11H19O2.Zn |
Molecular Weight | 431.944 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Zn++].[O-]C(=O)CCCCCCCCC=C.[O-]C(=O)CCCCCCCCC=C
InChI
InChIKey=YMCOHQVWOBMDCZ-UHFFFAOYSA-L
InChI=1S/2C11H20O2.Zn/c2*1-2-3-4-5-6-7-8-9-10-11(12)13;/h2*2H,1,3-10H2,(H,12,13);/q;;+2/p-2
DescriptionSources: https://www.fda.gov/ohrms/dockets/ac/04/briefing/4036B1_06_OTC%20Monograph%20Topical.htmCurator's Comment: description was created based on several sources, including
http://www.altmedrev.com/publications/7/1/68.pdf |
https://www.ncbi.nlm.nih.gov/pubmed/10991877
Sources: https://www.fda.gov/ohrms/dockets/ac/04/briefing/4036B1_06_OTC%20Monograph%20Topical.htm
Curator's Comment: description was created based on several sources, including
http://www.altmedrev.com/publications/7/1/68.pdf |
https://www.ncbi.nlm.nih.gov/pubmed/10991877
Undecylenic acid is unsaturated fatty acid, which naturally occurs in sweat, and is commercially produced by the vacuum distillation of castor bean oil. It is recognized as GRASE by FDA, and is marketed over the counter to treat skin infections and to relieve itching. Undecylenic acid acts by inhibition of morphogenesis from yeast to hyphae forms.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: map00061 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10991877 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | CRUEX Approved UseFor the cure of most tinea pedis (athlete's foot) and tinea corporis (ringworm). |
|||
Curative | CRUEX Approved UseFor the cure of most tinea pedis (athlete's foot) and tinea corporis (ringworm). |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | CRUEX Approved UseItching, burning, redness, irritation, scaling, soreness and discomfort which may accompany these conditions |
Doses
Dose | Population | Adverse events |
---|---|---|
2.2 g 3 times / day multiple, oral Dose: 2.2 g, 3 times / day Route: oral Route: multiple Dose: 2.2 g, 3 times / day Co-administed with:: nicotinic acid(50 mgm. morning and night) Sources: |
unhealthy, 56 years n = 1 Health Status: unhealthy Condition: psoriasis Age Group: 56 years Sex: M Population Size: 1 Sources: |
Disc. AE: Toxic labyrinthitis... AEs leading to discontinuation/dose reduction: Toxic labyrinthitis (1 patient) Sources: |
1 g 3 times / day multiple, oral Dose: 1 g, 3 times / day Route: oral Route: multiple Dose: 1 g, 3 times / day Sources: |
unhealthy, 8-14 years n = 4 Health Status: unhealthy Condition: psoriasis | NEURODERMATITIS Age Group: 8-14 years Population Size: 4 Sources: |
|
10 g 3 times / day multiple, oral Highest studied dose Dose: 10 g, 3 times / day Route: oral Route: multiple Dose: 10 g, 3 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: psoriasis Age Group: adult Sources: |
|
2 % 1 times / day multiple, topical Dose: 2 %, 1 times / day Route: topical Route: multiple Dose: 2 %, 1 times / day Co-administed with:: zinc undecylenate(0.2) Sources: |
unhealthy n = 29 Health Status: unhealthy Condition: TINEA PEDIS Population Size: 29 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Toxic labyrinthitis | 1 patient Disc. AE |
2.2 g 3 times / day multiple, oral Dose: 2.2 g, 3 times / day Route: oral Route: multiple Dose: 2.2 g, 3 times / day Co-administed with:: nicotinic acid(50 mgm. morning and night) Sources: |
unhealthy, 56 years n = 1 Health Status: unhealthy Condition: psoriasis Age Group: 56 years Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Screening for new compounds with antiherpes activity. | 1984 Oct |
|
Application of linear solvation energy relationships to polymeric pseudostationary phases in micellar electrokinetic chromatography. | 2001 Apr |
|
Convenient formation of 4-hydroxyalk-2-en-1-one functionality via A knoevenagel-type carbon chain elongation reaction of aldehyde with 1-arylsulfinylalkan-2-one. | 2001 Feb 23 |
|
Allergic contact dermatitis from undecylenic acid in a commercial antifungal nail solution. | 2002 Feb |
|
Determination of undecylenic and sorbic acids in cosmetic preparations by high performance liquid chromatography with electrochemical detection. | 2002 Nov 7 |
|
Surface functionalization of silicon nanoparticles produced by laser-driven pyrolysis of silane followed by HF-HNO3 etching. | 2004 May 25 |
|
Kinetic control of the photochemical reactivity of hydrogen-terminated silicon with bifunctional molecules. | 2005 May 24 |
|
Silicon nanoparticles: applications in cell biology and medicine. | 2006 |
|
Self-assembled thermo- and pH responsive micelles of poly(10-undecenoic acid-b-N-isopropylacrylamide) for drug delivery. | 2006 Dec 1 |
|
Well-defined carboxyl-terminated alkyl monolayers grafted onto H-Si(111): packing density from a combined AFM and quantitative IR study. | 2006 Jan 3 |
|
Simple fluorimetric liquid chromatographic method for the analysis of undecylenic acid and zinc undecylenate in pharmaceutical preparations. | 2006 Jun 30 |
|
UV photodissociation spectroscopy of oxidized undecylenic acid films. | 2006 Mar 16 |
|
Tailor-made olefinic medium-chain-length poly[(R)-3-hydroxyalkanoates] by Pseudomonas putida GPo1: batch versus chemostat production. | 2006 Mar 5 |
|
Grazing angle mirror-backed reflection (GMBR) for infrared analysis of monolayers on silicon. | 2006 Sep 14 |
|
Mechanisms of thermal decomposition of organic monolayers grafted on (111) silicon. | 2007 Jan 30 |
|
Structure and polymer form of poly-3-hydroxyalkanoates produced by Pseudomonas oleovorans grown with mixture of sodium octanoate/undecylenic acid and sodium octanoate/5-phenylvaleric acid. | 2007 Jan 30 |
|
Self-assembled monolayers with latent aldehydes for protein immobilization. | 2007 Jan-Feb |
|
Covalent biofunctionalization of silicon nitride surfaces. | 2007 May 22 |
|
Cell adhesion properties on photochemically functionalized diamond. | 2007 May 8 |
|
Determination of nateglinide in human plasma by high-performance liquid chromatography with pre-column derivatization using a coumarin-type fluorescent reagent. | 2007 Sep 5 |
|
A new concept in the topical treatment of onychomycosis with cyanoacrylate, undecylenic acid, and hydroquinone. | 2008 Apr |
|
Comparison of the skin sensitizing potential of unsaturated compounds as assessed by the murine local lymph node assay (LLNA) and the guinea pig maximization test (GPMT). | 2008 Jun |
|
Porous silicon for photosensitized formation of singlet oxygen in water and in simulated body fluid: two methods of modification by undecylenic acid. | 2009 Jun |
|
Electrochemical behavior of gold colloidal alkyl modified silicon surfaces. | 2009 Nov |
|
Stimulatory effect of undecylenic acid on mouse osteoblast differentiation. | 2010 Apr |
|
Simple surface modification of poly(dimethylsiloxane) for DNA hybridization. | 2010 Dec 6 |
|
Rapid approach to biobased telechelics through two one-pot thiol-ene click reactions. | 2010 Jun 14 |
|
Production of functionalized polyhydroxyalkanoates by genetically modified Methylobacterium extorquens strains. | 2010 Sep 16 |
Patents
Sample Use Guides
Undecylenic acid antifungal liquid should be applied to affected area topically.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10991877
To investigate effect of undecylenic acid on Candida albicans morphogenesis, cells were grown overnight at 30°C on YPD agar and harvested by scraping the cells from the plate and suspending in YPD broth. Two milliliters of cells at 106 cells/ml was distributed into tubes containing liner, approximately 0.5 g of liner per tube. The cultures were incubated at 39°C with agitation for 2 h; planktonic cells were analyzed microscopically to determine the percentage of cells with germ tubes. The presence of Undecylenic acid inhibited the appearance of germ tubes, with 10 μM UDA causing a sevenfold reduction.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C514
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
||
|
CFR |
21 CFR 333.210
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000089534
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
SUB15763MIG
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
402438
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
209-155-0
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
C29552
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
89748
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | RxNorm | ||
|
11179
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
388VZ25DUR
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
DBSALT001529
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
m11303
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | Merck Index | ||
|
388VZ25DUR
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
1724780
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
557-08-4
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
DTXSID90890497
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
4457
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD